Lanreotide Subcutaneous and Hepatic impairment
Result of checking the interaction of drug Lanreotide Subcutaneous and disease Hepatic impairment for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:In clinical trials, a reduced clearance of lanreotide was observed in subjects with moderate to severe hepatic impairment. Patients with moderate to severe hepatic impairment should begin treatment with lanreotide 60 mg. Caution should be exercised when using this agent in patients with moderate or severe hepatic impairment for an extended dosing interval.
Generic Name: lanreotide
Brand Name: Somatuline Depot
Synonyms: Lanreotide
Lanreotide Subcutaneous - zaburzenia czynności wątroby 
Lanreotide Subcutaneous - insuficiência hepática 
Lanreotide Subcutaneous - gangguan hati 
Lanreotide Subcutaneous - gangguan hati 
Lanreotide Subcutaneous - insufficienza epatica 
Lanreotide Subcutaneous - insuffisance hépatique 
Lanreotide Subcutaneous - Leberfunktionsstörung 
Lanreotide Subcutaneous - deterioro hepático 
Lanreotide Subcutaneous - печеночная недостаточность 
Lanreotide Subcutaneous - karaciğer yetmezliği 
Lanreotide Subcutaneous - اختلال كبدي 
Lanreotide Subcutaneous - 肝功能不全